Tevogen says S-1 does not relate to any previously undisclosed dilutive issuance

Tevogen Bio notes that the company filed a Registration Statement on Form S-1 on June 21, which was declared effective by the Securities and Exchange Commission on August 2, to register the issuance of earnout shares and shares underlying outstanding warrants to purchase the company’s common stock as well as the resale of shares and warrants by existing securityholders. “Today, Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities,” the company stated. Tevogen CEO Dr. Ryan Saadi stated, “Given the recent volatility across broader stock market indices as well as in Tevogen stock, I want to express management’s conviction in the company’s strategy and outlook. Our ultimate objective of helping patients and doctors by providing affordable and accessible therapies remains unwavering. Our efficient business model uniquely underscores this objective. I anticipate the company’s most recent financing, for up to $50 million, which finalized in July, will allow us to continue to fund existing operations into the future.”